

SCHEDULE OF INVESTMENTS

March 31, 2026

BIOTECHNOLOGY FUND

	SHARES	VALUE		SHARES	VALUE
COMMON STOCKS - 99.6%			COMMON STOCKS - 99.6% (continued)		
BIOTECHNOLOGY - 72.9%			BIOTECHNOLOGY - 72.9% (continued)		
Amgen, Inc.	20,093	\$ 7,069,722	Krystal Biotech, Inc.* ^a	2,474	\$ 639,084
Gilead Sciences, Inc.	48,042	6,695,614	Legend Biotech Corp. ADR*	35,054	634,127
Vertex Pharmaceuticals, Inc.*	12,119	5,411,618	Intellia Therapeutics, Inc.*	49,463	634,116
Regeneron Pharmaceuticals, Inc.	6,224	4,808,911	ADMA Biologics, Inc.*	65,635	591,371
Alnylam Pharmaceuticals, Inc.*	10,632	3,517,810	Total Biotechnology		97,590,509
Insmed, Inc.*	20,277	3,315,695	PHARMACEUTICALS - 20.6%		
BeOne Medicines Ltd. ADR*	10,395	3,087,003	AbbVie, Inc.	45,923	9,987,793
United Therapeutics Corp.*	4,711	2,793,529	AstraZeneca plc	10,974	2,164,292
Biogen, Inc.*	14,803	2,713,834	Viatis, Inc.	150,073	2,027,486
Royalty Pharma plc — Class A	55,739	2,673,800	Alkermes plc*	56,068	1,982,565
illumina, Inc.*	19,053	2,348,473	Jazz Pharmaceuticals plc*	10,448	1,975,194
Revolution Medicines, Inc.*	23,475	2,282,944	Neurocrine Biosciences, Inc.*	14,527	1,913,787
Moderna, Inc.*	43,818	2,225,954	Vaxcyte, Inc.*	26,383	1,533,116
Argenx SE ADR*	2,961	2,162,270	Ascendis Pharma A/S ADR*	5,974	1,366,433
Incyte Corp.*	22,317	2,100,476	Madrigal Pharmaceuticals, Inc.*	2,329	1,219,162
Bridgebio Pharma, Inc.* ^a	26,764	1,987,495	Mirum Pharmaceuticals, Inc.*	13,080	1,208,331
Roivant Sciences Ltd.*	68,372	1,893,904	Protagonist Therapeutics, Inc.*	11,198	1,180,269
Ionis Pharmaceuticals, Inc.*	24,870	1,867,488	Rhythm Pharmaceuticals, Inc.*	12,158	1,057,381
Exelixis, Inc.*	40,607	1,741,634	Total Pharmaceuticals		27,615,809
BioMarin Pharmaceutical, Inc.*	29,738	1,679,900	HEALTHCARE-PRODUCTS - 4.8%		
Apellis Pharmaceuticals, Inc.*	41,107	1,653,735	Natera, Inc.*	14,145	2,828,859
Arrowhead Pharmaceuticals, Inc.*	26,370	1,653,399	Guardant Health, Inc.*	20,606	1,903,376
Cytokinetics, Inc.*	24,093	1,587,970	Twist Bioscience Corp.*	20,054	952,966
CRISPR Therapeutics AG*	32,054	1,524,809	GRAIL, Inc.*	12,830	663,054
Halozyne Therapeutics, Inc.*	22,712	1,467,877	Total Healthcare-Products		6,348,255
BioNTech SE ADR*	16,159	1,436,212	HEALTHCARE-SERVICES - 1.3%		
Axsome Therapeutics, Inc.*	8,171	1,381,062	Medpace Holdings, Inc.*	3,540	1,699,873
Cogent Biosciences, Inc.*	34,752	1,337,604	Total Common Stocks		
Arcelx, Inc.*	11,645	1,337,079	(Cost \$78,991,658)		133,254,446
TG Therapeutics, Inc.*	39,225	1,303,054	RIGHTS - 0.0%		
PTC Therapeutics, Inc.*	18,935	1,290,042	BIOTECHNOLOGY - 0.0%		
Scholar Rock Holding Corp.*	25,883	1,272,408	Akero Therapeutics, Inc.* ^b	17,387	2
Amicus Therapeutics, Inc.*	76,280	1,103,009	CONSUMER, NON-CYCLICAL - 0.0%		
Apogee Therapeutics, Inc.*	12,066	1,015,595	Sanofi S.A.		
Kymera Therapeutics, Inc.*	11,658	970,995	Expiring 06/30/32* ^b	8,866	1
Viking Therapeutics, Inc.* ^a	29,278	952,706	Total Rights		3
Summit Therapeutics, Inc.*	49,213	933,078	(Cost \$—)		
Nuvalent, Inc. — Class A*	9,053	927,480			
ACADIA Pharmaceuticals, Inc.*	40,673	905,381			
Traverse Therapeutics, Inc.*	30,251	898,757			
Sarepta Therapeutics, Inc.*	40,226	875,318			
Celcuity, Inc.*	7,658	874,084			
Arcutis Biotherapeutics, Inc.*	36,923	869,906			
Veracyte, Inc.*	26,685	859,524			
Liquidia Corp.*	22,146	835,790			
Beam Therapeutics, Inc.*	31,896	760,082			
Ultragenyx Pharmaceutical, Inc.*	34,041	713,159			
Praxis Precision Medicines, Inc.*	2,092	674,021			
Soleno Therapeutics, Inc.*	19,659	658,183			
Recursion Pharmaceuticals, Inc. — Class A*	208,931	641,418			
				FACE AMOUNT	
			REPURCHASE AGREEMENTS^c - 0.4%		
			J.P. Morgan Securities LLC		
			issued 03/31/26 at 3.66% due 04/01/26	\$ 311,357	311,357
			Bank of America Securities, Inc.		
			issued 03/31/26 at 3.65% due 04/01/26	282,954	282,954
			Total Repurchase Agreements		594,311
			(Cost \$594,311)		
			Total Investments - 100.0%		
			(Cost \$79,585,969)	\$	133,848,760
			Other Assets & Liabilities, net - 0.0%		
					64,308
			Total Net Assets - 100.0%		
				\$	133,913,068

BIOTECHNOLOGY FUND

- * Non-income producing security.
- ^a All or a portion of this security is on loan at March 31, 2026.
- ^b Value determined based on Level 3 inputs.
- ^c Repurchase Agreements.

ADR — American Depositary Receipt

LLC — Limited Liability Company

plc — Public Limited Company